MBP 3.23% 3.0¢ metabolic pharmaceuticals limited

+ data and comment +

  1. 22,691 Posts.
    MBP: http://www.metabolic.com.au/

    Financial: About 216.5 mill shares and about 6 mill. options.
    Cash: About $24 mill?

    Metabolic Pharmaceuticals develops novel therapies for metabolic diseases, eg obesity, type 2 diabetes, iron overload diseases and osteoporosis.

    MBP has some drugs under development and the obesity drug AOD 9604 is strategically important as obesity is widespread in the western world:

    1. OBESITY DRUG AOD9604

    Fast Facts: http://www.obesity.org/subs/fastfacts/aoafactsheets.shtml

    Extract: "Approximately 127 million adults in the U.S. are overweight, 60 million obese, and 9 million severely obese.

    POSITIVE RESULTS FROM AOD9604 OBESITY DRUG ORAL PHASE 2A HUMAN CLINICAL TRIAL -Date 27/8/2002:

    http://stocknessmonster.com/news-item?S=MBP&E=ASX&N=193843

    BRESAGEN TO DEVELOP PRODUCTION METHOD FOR METABOLIC'S AOD9604 OBESITY DRUG (29/10/02):

    http://stocknessmonster.com/news-item?S=MBP&E=ASX&N=196980

    Positive outcomes from a 7 day trial of Phase 2a, drug AOD9604 trial-Date: 3/3/2003:.

    http://stocknessmonster.com/news-item?S=MBP&E=ASX&N=201482

    Extract: "The principle of AOD9604, already proven in animal studies, is to mimic the natural fat reducing properties of human growth hormone without producing any effects on blood sugar control or growth. In the 10 mg dose group, the overall weight loss was 1.0 kg compared to 0.4 kg in the placebo group, and in the 20 older volunteers the weight loss was 0.8 kg compared to a weight gain of 0.1 kg in the placebo group".

    Investor update, date 21/5/03
    http://stocknessmonster.com/news-item?S=MBP&E=ASX&N=204500

    Extract: "Success for prototype AOD GM seed. Metabolic has been working with SemBioSys Genetics Inc. of Canada to assess the feasibility of producing a genetically modified (GM) food containing AOD9604.

    It is proposed that the GM food will be primarily used as a veterinary application to reduce back fat in pigs and obesity in companion animals.

    A feasibility study conducted by Australian company, BresaGen Ltd, has successfully concluded that AOD9604 can be manufactured using recombinant processes (genetically engineered bacteria).

    This well-established technology is currently usedin the manufacture of many biopharmaceuticals, such as insulin and growth hormone.

    The feasibility study confirmed that AOD9604 can be made efficiently in bacteria. BresaGen has delivered a sample to Metabolic and our laboratory tests show it is identical to synthetically produced AOD9604, both chemically and in terms of biological activity".

    Shareholder Update of 28 July 2003:

    http://stocknessmonster.com/news-item?S=MBP&E=ASX&N=206672

    1. Phase 2B trial of the obesity drug AOD 9604 -Three hundred patients to take part. Duration: Three months.

    Patient screening is scheduled to start in September 2003 and the first patient is expected to commence treatment in October 2003.

    2. From the FDA boss, mr McClellan:

    “…. one key part of the FDA’s new medical innovation initiative is to try to facilitate the development of better treatments for obesity and diabetes. These are areas where we think regulatory pathways could be improved or better defined, and where we intend to give priority attention to potentially valuable new products.

    3. Favourable toxicity draft reports
    Draft reports on 3 month toxicity studies in monkeys and rats have been received and are
    favourable.

    Gerry
    Please do your own research and you decide if and when to buy, hold or sell any stocks.




 
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.